Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07277998
NA

Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

Sponsor: Karachi Medical and Dental College

View on ClinicalTrials.gov

Summary

Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical improvement in mouth opening, burning sensation, and mucosal flexibility compared to corticosteroid therapy alone.

Official title: Clinical Efficacy of Alternating Intralesional Triamcinolone Acetonide and Platelet-Rich Plasma Compared to Triamcinolone Alone in Patients With Oral Submucous Fibrosis: A Two-Arm Interventional Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2026-03

Completion Date

2026-09

Last Updated

2025-12-11

Healthy Volunteers

No

Interventions

BIOLOGICAL

Platelet-Rich Plasma (PRP) Injections

Autologous Platelet-rich plasma (PRP) injected intralesionally at standard volume for Oral submucous fibrosis (OSF) treatment, administered every alternate week.

DRUG

Triamcinolone Acetonide

Triamcinolone acetonide 10 mg/mL administered intralesionally once weekly.

Locations (1)

Abbasi Shaheed Hospital

Karachi, Sindh, Pakistan